If you would like to write for this, or any other Emerald publication, then please use our Emerald for Authors service information about how to choose which publication to write for and submission guidelines are available for all. Please visit www.emeraldinsight.com/authors for more information.
About Emerald www.emeraldinsight.comEmerald is a global publisher linking research and practice to the benefit of society. The company manages a portfolio of more than 290 journals and over 2,350 books and book series volumes, as well as providing an extensive range of online products and additional customer resources and services.Emerald is both COUNTER 4 and TRANSFER compliant. The organization is a partner of the Committee on Publication Ethics (COPE) and also works with Portico and the LOCKSS initiative for digital archive preservation.
AbstractPurpose -Tissue engineering (TE) offers treatments for chronic, life threatening, degenerative illnesses and possibilities for restoring cellular or organ functions that have been lost due to injuries or hereditary conditions. However, a prerequisite for the use of TE products as part of future therapies is the development of strategies for safe and efficient supply chain management and versatile services spanning from product development to a follow-up period of possibly decades. The present study aims to explore the future needs for services and extended supply chains for safe delivery of health care, procurement, distribution and long-term follow-up of TE products and therapies. Design/methodology/approach -Studies in operational disciplines and coordination systems for different types of supply chains and service networks are used to formulate a framework for developing services throughout product lifecycle. Case examples of TE products are presented to demonstrate complexity, microbial risks, services and long-term follow-up. The role of logistics and the necessary services are identified for products classified into experimental, therapy and standard products. Findings -The paper finds that, through the stages, the importance of logistics increases from an enabler to becoming a strategic tool, emphasizing logistics requirements in establishing a viable TE supply chain. New dimensions to existing service operations frameworks are needed where proactive tissue sourcing, long follow-up periods, short shelf life and biological risks call for enforcing flexible services with tissue banks, detailed tracing, authorization and regulation. Originality/value -The paper presents the discovery of the logistics services and service institutions that will become imperatives for the future success of TE products and therapies.